IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
SWISS MEDICAL WEEKLY. Bd. 151. 2021 S. 25-26
Erscheinungsjahr: 2021
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Finn, Richard S. (Autor)
Qin, Shukui (Autor)
Ikeda, Masafumi (Autor)
Galle, Peter R. (Autor)
Ducreux, Michel (Autor)
Mertens, Joachim (Autor)
Kim, Tae-You (Autor)
Kudo, Masatoshi (Autor)
Lim, Ho Yeong (Autor)
Breder, Valeriy (Autor)
Merle, Philippe (Autor)
Kaseb, Ahmed (Autor)
Li, Daneng (Autor)
Feng, Yin-Hsun (Autor)
Verret, Wendy (Autor)
Nicholas, Alan (Autor)
Li, Lindong (Autor)
Ma, Ning (Autor)
Zhu, Andrew X. (Autor)
Cheng, Ann-Lii (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
